CARMA Cell Therapies (MAXCYTE)

Shruti Abbato, EVP, Business Development
Gaithersburg, MD
CARMA Cell Therapies is a wholly-owned subsidiary of MaxCyte and is focused on the advancement of novel mRNA-based cell therapies for cancer and other diseases with serious unmet needs. MaxCyte developed CARMA, a novel and proprietary platform for the development of non-viral, human messenger RNA (mRNA)-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies. CARMA utilizes MaxCyte’s Flow Electroporation® technology for highly efficient, non-viral, delivery of one or more mRNA into unmanipulated peripheral blood mononuclear cells (PBMCs) or other immune cells, resulting in a unique class of cell therapies with the potential for improved safety and efficacy over conventional cell therapy approaches. CARMA also offers the potential for a significantly streamlined, scalable, and cost-effective GMP manufacturing process without the complexity of virus-based products. MaxCyte expects CARMA Cell Therapies to be self-funded by end of 2020.

By using this website you agree to accept our Privacy Policy and Terms & Conditions